{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:44:07Z","timestamp":1774021447239,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jgo.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T02:06:33Z","timestamp":1593741993000},"page":"1309-1315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Shuling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad L.","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kelsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Support Cancer Ther"},{"issue":"10","key":"10.1016\/j.jgo.2020.06.018_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0025","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","volume":"16","author":"Dulisse","year":"2013","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0030","first-page":"113","article-title":"Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2020.06.018_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002820-200505000-00001","article-title":"Quality of life and chemotherapy-induced neutropenia","volume":"28","author":"Padilla","year":"2005","journal-title":"Cancer Nurs"},{"issue":"21","key":"10.1016\/j.jgo.2020.06.018_bb0040","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0045","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2020.06.018_bb0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.06.018_bb0055","author":"Crawford"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/107327480301000607","article-title":"Evidence-based use of colony-stimulating factors in elderly cancer patients","volume":"10","author":"Lyman","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.jgo.2020.06.018_bb0065","author":"Food and Drug Administration"},{"issue":"9","key":"10.1016\/j.jgo.2020.06.018_bb0070","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jama.2018.9014","article-title":"Uptake of the biologic Filgrastim and its biosimilar product among the medicare population","volume":"320","author":"Kozlowski","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgo.2020.06.018_bb0075","author":"Administration FaD"},{"key":"10.1016\/j.jgo.2020.06.018_bb0080","author":"Administration FaD"},{"issue":"3","key":"10.1016\/j.jgo.2020.06.018_bb0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2020.06.018_bb0095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/1078155215625459","article-title":"Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review","volume":"22","author":"Mitchell","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.jgo.2020.06.018_bb0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/MLR.0b013e318215c42e","article-title":"Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy","volume":"49","author":"Rajan","year":"2011","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jgo.2020.06.018_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","article-title":"Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?","volume":"40","author":"Weycker","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgo.2020.06.018_bb0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1472-6963-14-189","article-title":"Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis","volume":"14","author":"Weycker","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"2 Suppl","key":"10.1016\/j.jgo.2020.06.018_bb0115","first-page":"15","article-title":"Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma treated with chemotherapy","volume":"9","author":"Scott","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jgo.2020.06.018_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CLEP.S105613","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0125","first-page":"439","article-title":"Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with Colony-stimulating factor","volume":"25","author":"Weycker","year":"2017","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.jgo.2020.06.018_bb0135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jgo.2020.06.018_bb0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1472-6963-13-60","article-title":"Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases","volume":"13","author":"Weycker","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"10.1016\/j.jgo.2020.06.018_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/oem.2004.014472","article-title":"An incidence density sampling program for nested case-control analyses","volume":"61","author":"Richardson","year":"2004","journal-title":"Occup Environ Med"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2531050","article-title":"More on \u201cbiased selection of controls for case-control analyses of cohort studies\u201d","volume":"42","author":"Robins","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.jgo.2020.06.018_bb0160","author":"Food and Drug Administration"},{"key":"10.1016\/j.jgo.2020.06.018_bb0165","author":"Food and Drug Administration"},{"key":"10.1016\/j.jgo.2020.06.018_bb0170","author":"Food and Drug Admnistration"},{"issue":"10","key":"10.1016\/j.jgo.2020.06.018_bb0175","first-page":"4377","article-title":"Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies","volume":"24","author":"Li","year":"2016","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0889-8588(05)70344-0","article-title":"Chemotherapy and neutropenia","volume":"10","author":"Kim","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2008.10.014","article-title":"Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization","volume":"72","author":"Crea","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0190","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1634\/theoncologist.10-2-138","article-title":"Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin\u2019s lymphoma","volume":"10","author":"Blayney","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2020.06.018_bb0195","series-title":"Modern epidemiology","author":"Rothman","year":"2008"},{"issue":"2","key":"10.1016\/j.jgo.2020.06.018_bb0200","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JOP.2014.002337","article-title":"Centers for Medicare and Medicaid Services: using an episode-based payment model to improve oncology care","volume":"11","author":"Kline","year":"2015","journal-title":"J Oncol Pract"},{"issue":"5","key":"10.1016\/j.jgo.2020.06.018_bb0205","article-title":"Making sense of advanced payment models","volume":"23","author":"McAneny","year":"2017","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.jgo.2020.06.018_bb0210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","article-title":"A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies","volume":"63","author":"Bosco","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jgo.2020.06.018_bb0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2020.06.018_bb0220","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820300898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820300898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:51:22Z","timestamp":1761817882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820300898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1879406820300898"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.06.018","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}